Polymorphism of p53 Gene Codon 72 in Endometrial Cancer: Correlation with Tumor Grade and Histological Type

Kafshdooz, Taiebeh; Tabrizi, Ali Dastranj; Ardabili, Seyyed Mojtaba Mohaddes; Kafshdooz, Leila; Ghojazadeh, Morteza; Gharesouran, Jalal; Abdii, Ali; Alizadeh, Hamideh

doi:10.7314/apjcp.2014.15.22.9603

Cited by 10 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For more effective therapies, a prerequisite may be that the target of choice is commonly involved in GC. The p53 protein has suppressive effects in tumours, and p53 gene alterations are widespread in cancer (7,8,(20)(21)(22). Although mutated forms of p53 are common in GC tissues, their pharmacological significance remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin

Yuan

Zhang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

The present study aimed to investigate the role of tumour protein 53 isoform b (p53β) on human gastric cancer (GC) cell lines treated with recombinant mutated human tumour necrosis factor (rmhTNF) and cisplatin. The Cell Counting Kit‑8 assay was used to assess growth in the GC cell lines MKN45 and SGC7901, following treatment with rmhTNF in the presence or absence of cisplatin. Levels of p53β and bcl‑2 apoptosis regulator (bcl‑2) mRNA were assessed using reverse transcription‑polymerase chain reaction. The results demonstrated that growth was significantly inhibited by either cisplatin or rmhTNF treatments alone in MKN45 cells, and combination treatment with cisplatin and rmhTNF had a synergistic effect on growth inhibition of MKN45 cells. Notably, these observations were not evident in SGC7901 cells, where a mutant form of p53 is present. Treatment of MKN45 cells with rmhTNF did not affect bcl‑2 or p53β mRNA expression levels. However, treatment of MKN45 cells with cisplatin induced upregulation of p53β and downregulation of bcl-2 mRNA expression levels, and these effects were enhanced by combination treatment with rmhTNF. Pearson correlation analysis revealed a negative correlation between the expression of p53β and bcl‑2 mRNA, and a negative correlation between bcl-2 mRNA expression and the inhibition of cell growth. In conclusion, the inhibitory effect of cisplatin on the growth of MKN45 GC cells was enhanced by rmhTNF via unknown mechanisms that involved p53β, indicating that p53β may be an appropriate therapeutic target for the treatment of GC.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin

Yuan

Zhang

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Regards to other types of endometrial carcinoma, it is worth to note that clear cell and mucinous carcinoma can be found in the EPs also (30). In the minimal endometrial serous carcinoma or EIC, the common genetic mutation which can be confirmed with IHC method is P53 mutation (31). Therefore in the suspicious polyps, IHC staining for P53 will be useful in confirmation of diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Histologic Features and Differential Diagnosis of Endometrial Polyps; An Update and Review

Tabrizi¹

2016

IJWHR

View full text Add to dashboard Cite

IntroductionAmong the endometrial lesions, endometrial polyps (EPs) are commonly seen in the premenopausal and postmenpuasal age group and are found in 25% of endometrial specimens performed for abnormal uterine bleeding (1). EPs are generally considered as local hyperplasitic lesions of endometrial stroma which covered by epithelium. These lesions are seen single or multiple, sessile or pedunculated and the size range differs from millimetres to centimetres. In 10% of cases they mimic endocervical polyp due to prolapsus from external os (2,3). In a case of sufficient clinical, hysteroscopic and imaging information, the histologic diagnosis is usually straightforward. From clinical and prognostic standpoint, it should be emphasized that rarely these lesion may harbour premalignant and malignant lesions particularly in older age group. Therefore careful histologic examination for rule out of raised malignant lesions should be considered. In the other hand in rare cases these lesions may show metastatic involvement particularly from lobular breast carcinoma. Prevalence of these lesions in association with clinical presentation and histologic features will be presented and differential diagnosis with special emphasis on rule out of malignant lesions will be discussed. PrevalenceIn the 2402 office hysteroscopy performed on women with mean age of 39.4 years old for several indications, the prevalence of EP was 27.2% (4). Based on used diagnostic method and study group the mentioned rate varies between 6% to 32% and this rate increases with age (5-7). In another large study carried out on 686 Danish women in range of 20-79 years of old who accepted to be examined by both transvaginal sonography and saline contrast sonohysterography, the prevalence of EP was 7.8% (5). In this study the EPs were rare (0.9%) between young women and in women older than 30 years the prevalence was 9.2%. EPs are rarely found in OCP user whereas in the women who were on hormone replacement therapy the prevalence was much higher (2.1% vs. 25%) (5). Respect to hormones as an etiologic factor, high frequency of endometrial hyperplasia was found in the non-polyploid region of endometrium in premenopausal and postmenopausal women (8). Clinical PresentationThe usual clinical presentations of EPs may include menorrhagia, intermenstrual bleeding, postmenopausal bleeding and infertility. However the majority of patients may be asymptomatic and the prevalence could be similar in symptomatic and asymptomatic women (5). These findings indicates that there is no consistent relationship between abnormal uterine bleeding and existence of EPs and why hysteroscopic resection of EPs does not always result in relief of symptoms (9). A pathologist should be alert that in the most cases of protruded EPs, the usual clinical diagnosis will be endocervical polyp by the gynaecologist. Regard to tamoxifen, EPs are the most common pathology that could be seen in these patients. In these patients the prevalence of AbstractAmong the endometrial lesions, endometrial poly...

show abstract

“…In the last decade the possible association of endometrium cancer with p53 polymorphism codon 72 has been investigated in several human populations. A positive association with the Pro variant has been observed in Korean and other Asiatic populations but not in Caucasian populations [2][3][4][5][6]. In Japanese women a positive association has been found with Arg variant [7].…”

Section: Introductionmentioning

confidence: 92%

P53 Codon 72 and Endometrium Cancer

Gloria‐Bottini¹,

Nicotra

Spina³

et al. 2015

J. Can. Res. Updates

View full text Add to dashboard Cite

Background: The possible role p53 codon 72 in endometrium cancer has been investigated in several human populations: a positive association with the Pro variant has been observed in Asiatic but not in Caucasian populations. We reasoned that polymorphisms associated with endometrium cancer may interact with p53 codon 72 influencing the degree of association between this polymorphism and cancer. Methods: Sixty nine women admitted to the hospital for endometrium cancer and 473 healthy subjects were studied in the White population of Rome. Verbal consent was obtained from these subjects to participate to the study that was approved by the Department. P53 codon 72, ADA1, ADA6 and PTPN22 genotypes were determined by DNA analysis Statistical analysis were performed by using commercial software (SPSS). Results: The joint genotype carrying the *Pro allele of p53 codon 72and the ADA1*2 allele, the joint genotype carrying the *Pro allele and ADA6 *1 allele and the joint genotype carrying the *Pro allele and *C/*C genotype of PTPN22 show a proportion greater in cancer than in controls. The proportion of *Pro allele carriers in endometrium cancer shows a positive correlation (p=0.019) with the number of genetic factors considered i.e. ADA1,ADA6, PTPN22. Conclusion: Our data suggest that the strength of association between the disease and p53 codon 72 depends on other genetic factors. Thus the different patterns of association between p53 codon 72 and endometrium cancer observed among human populations could be at least in part related to differences in allelic frequencies of these genetic factors.

show abstract

Polymorphism of p53 Gene Codon 72 in Endometrial Cancer: Correlation with Tumor Grade and Histological Type

Cited by 10 publications

References 22 publications

Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin

Effect of p53β on human gastric cancer cells treated with recombinant mutated human TNF and cisplatin

Histologic Features and Differential Diagnosis of Endometrial Polyps; An Update and Review

P53 Codon 72 and Endometrium Cancer

Contact Info

Product

Resources

About